{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:50:57Z","timestamp":1740178257432,"version":"3.37.3"},"reference-count":27,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophilia is an X-linked congenital bleeding disorder for which factor replacement is life-saving but complicated by the sequelae of chronic hepatitis C virus (HCV) infection acquired decades ago. Although antiviral therapy clears HCV and reduces end-stage liver disease (ESLD), it may not reverse cirrhosis or prevent hepatocellular cancer (HCC). This was a retrospective cohort study of 121 men with hemophilia and HCV infection cared for at the Hemophilia Center of Western Pennsylvania to determine the incidence and predictors of ESLD and HCC. ESLD and HCC predictors were analyzed using Fisher exact test, and HCV-associated outcomes by Kaplan-Meier time-to-event and Cox proportional hazards regression analyses. At a\u00a0mean 54 years (36-80) duration of HCV, ESLD occurred in 24 (19.8%), 0.365 per 100 person-years (py); and HCC in 7 (5.8%), 0.106 per 100 py. All 46 (38.0%) alive when HCV antiviral therapy became available, received it. Overall, 31 (25.6%) were HIV+. The leading causes of death were ESLD in 11 (32.3%), bleeding in 9 (26.5%), and HCC in 6 (17.6%). Major risk factors for ESLD included platelets &amp;lt;100\u2009\u00d7 103\/\u03bcL (odds ratio [OR],\u00a06.009; P\u00a0=\u00a0.012) and HIV infection (OR,\u00a03.883; P\u00a0=\u00a0.001). The major predictors of HCC were ESLD (OR,\u00a011.476; P\u00a0=\u00a0.003) and platelets &amp;lt;100\u2009000\/\u03bcL (OR,\u00a06.159; P\u00a0=\u00a0.014). No antiviral-treated patient developed ESLD, P\u00a0=\u00a0.001. For men with hemophilia, the sequelae of chronic HCV infection were significant. The major risk factors for ESLD were platelets &amp;lt;100\u2009000\/\u03bcL and HIV infection. Despite antiviral therapy, ESLD is the most significant predictor of HCC, and ESLD is the leading cause of death.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014350","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T17:53:20Z","timestamp":1727978000000},"page":"5767-5772","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of liver disease outcomes in individuals with hemophilia and HCV infection"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3527-1834","authenticated-orcid":false,"given":"Ilias","family":"Christodoulou","sequence":"first","affiliation":[{"name":"1Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8300-5947","authenticated-orcid":false,"given":"Scott","family":"Rothenberger","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA"},{"name":"2Department of Medicine and Center for Research on Healthcare, University of Pittsburgh Medical Center, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-5379","authenticated-orcid":false,"given":"Margaret V.","family":"Ragni","sequence":"additional","affiliation":[{"name":"1Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA"},{"name":"2Department of Medicine and Center for Research on Healthcare, University of Pittsburgh Medical Center, Pittsburgh, PA"},{"name":"3Division Classical Hematology, Department of Medicine, University of Pittsburgh Medical Center, and The Hemophilia Center of Western Pennsylvania, Pittsburgh, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"issue":"2","key":"2024112214455917400_bib1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/bjh.17438","article-title":"Viral hepatitis in haemophilia: historical perspective and current management","volume":"195","author":"Isfordink","year":"2021","journal-title":"Br J Hematol"},{"issue":"1","key":"2024112214455917400_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jhep.2013.08.010","article-title":"Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disrders","volume":"60","author":"van de Putte","year":"2014","journal-title":"J Hepatol"},{"issue":"5","key":"2024112214455917400_bib3","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/hae.13244","article-title":"Progression of hepatitis C in the haemophiliac population in Ireland after 30 years of infection in the pre-DAA treatment era","volume":"23","author":"Murphy","year":"2017","journal-title":"Haemophilia"},{"issue":"19","key":"2024112214455917400_bib4","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1182\/bloodadvances.2023010723","article-title":"Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy","volume":"7","author":"La Mura","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2024112214455917400_bib5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1086\/319273","article-title":"Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with haemophilia and hepatitis C infection","volume":"183","author":"Ragni","year":"2001","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"2024112214455917400_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2516.2010.02366.x","article-title":"Impact of HIV on liver fibrosis in men with hepatitis C infection and hemophilia","volume":"17","author":"Ragni","year":"2011","journal-title":"Haemophilia"},{"issue":"2","key":"2024112214455917400_bib7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2516.2008.01935.x","article-title":"Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection","volume":"15","author":"Ragni","year":"2009","journal-title":"Haemophilia"},{"issue":"1","key":"2024112214455917400_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2516.2012.02905.x","article-title":"Liver transplant outcomes in HIV(+) haemophilic men","volume":"19","author":"Ragni","year":"2013","journal-title":"Haemophilia"},{"issue":"6","key":"2024112214455917400_bib9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/lt.24688","article-title":"Hemophilia liver transplantation observational study","volume":"23","author":"Ragni","year":"2017","journal-title":"Liver Transpl"},{"issue":"5","key":"2024112214455917400_bib10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2020.09.065","article-title":"Fibrosis regression after eradication of hepatitis C virus: from bench to bedside","volume":"160","author":"Rockey","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"2024112214455917400_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/hae.13668","article-title":"Incidence and risk factors for hepatocellular cancer in individuals with haemophilia: a national inpatient sample study","volume":"25","author":"Thalappillil","year":"2019","journal-title":"Haemophilia"},{"issue":"5","key":"2024112214455917400_bib12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.14607","article-title":"Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct-acting antiviral agents: a national inpatient sample study","volume":"28","author":"Yang","year":"2022","journal-title":"Haemophilia"},{"issue":"7","key":"2024112214455917400_bib13","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1007\/s10620-020-06457-2","article-title":"Nonalcoholic fatty liver disease risk factors affect liver-related outcomes after direct-acting antiviral treatment for hepatitis C","volume":"66","author":"Benhammou","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2024112214455917400_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"suppl 1","key":"2024112214455917400_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jth.15189","article-title":"Mortality in congenital hemophilia A \u2013 a systematic literature review","volume":"19","author":"Hay","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024112214455917400_bib16","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jama.1972.03200180052024","article-title":"Hepatitis and clotting factor concentrates","volume":"221","author":"Kasper","year":"1972","journal-title":"J\u00a0Am Med Assoc"},{"issue":"2","key":"2024112214455917400_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidelines by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"2024112214455917400_bib18","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA Clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review","volume":"158","author":"Loomba","year":"2020","journal-title":"Gastroenterology"},{"key":"2024112214455917400_bib19","unstructured":"National Bleeding Disorders Foundation\n          . Recommendations on screening for development of hepatocellular cancer in persons hepatitis B and C. 2023. Accessed 19 January 2024. https:\/\/www.hemophilia.org\/healthcare-professionals\/guidelines-on-care\/masac-documents\/masac-document-281-masac-recommendations-on-screening-for-development-of-hepatocellular-cancer-in-persons-with-hepatitis-b-and-c."},{"issue":"5","key":"2024112214455917400_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"issue":"6","key":"2024112214455917400_bib21","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histologic grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J\u00a0Hepatol"},{"issue":"9055","key":"2024112214455917400_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DISVIRC groups","volume":"1349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"issue":"12","key":"2024112214455917400_bib23","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary epidemiology of chronic liver disease and cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2024112214455917400_bib24","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1111\/hae.14637","article-title":"Diabetes, hepatitis C and human immunodeficiency virus influence hypertension risk differently in cohorts of haemophilia patients, veterans and the general population","volume":"28","author":"Barnes","year":"2022","journal-title":"Haemophilia"},{"issue":"2","key":"2024112214455917400_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1055\/s-0037-1604091","article-title":"Platelets as modulators of liver diseases","volume":"44","author":"Lisman","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"2024112214455917400_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.asjsur.2020.10.027","article-title":"Thrombocytopenia predicts the prognosis of hepatocellular carcinoma patients with Ishak score 6 after hepatectomy: a propensity score matching analysis","volume":"44","author":"Zhang","year":"2021","journal-title":"Asian J Surg"},{"issue":"6","key":"2024112214455917400_bib27","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood.V75.6.1267.1267","article-title":"Hemorrhagic sequelae of immune thrombocytopenic purpura (ITP) in HIV-infected hemophiliacs","volume":"75","author":"Ragni","year":"1990","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5767\/2314954\/blooda_adv-2024-014350-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5767\/2314954\/blooda_adv-2024-014350-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T14:46:29Z","timestamp":1732286789000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/22\/5767\/517941\/Predictors-of-liver-disease-outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":27,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014350","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}